Enlicitide Decanoate: Dosing Protocols
Dosing guidelines, reconstitution, and administration information
๐TL;DR
- โข2 dosing protocols documented
- โขReconstitution instructions included
- โขStorage: Storage conditions for enlicitide tablets have not been publicly disclosed in detail from clinical trial protocols. Standard oral tablet storage at room temperature, protected from moisture, is expected.
Protocol Quick-Reference
LDL cholesterol reduction in ASCVD risk patients
Dosing
Amount
20 mg
Frequency
Once daily
Duration
Ongoing
Step-wise Titration
Administration
Route
OralSchedule
N/A (oral tablet)
Timing
Once-daily oral tablet; taken on an empty stomach (30 minutes before first meal of the day based on Phase 2b protocol)
Cycle
Duration
Ongoing (continuous treatment)
Repeatable
Yes
Preparation & Storage
โ Ready-to-use โ no reconstitution required
Storage: Room temperature; protect from moisture
โ๏ธ Suggested Bloodwork (5 tests)
When:
Why:
When:
Why:
When:
Why:
When:
Why:
When:
Why:
๐ก Key Considerations
- โInvestigational drug - not yet approved by any regulatory authority
- โFDA submission expected early 2026
- โUsed as add-on to existing statin and lipid-lowering therapy
- โNo dose adjustment for body weight reported in clinical trials
Unlock dosing protocols
Free access to research-backed dosing information for all peptides.
150+ peptide profiles ยท 30+ comparisons ยท 18 research tools
| Purpose | Dose | Frequency | Duration | Notes |
|---|---|---|---|---|
| Hypercholesterolemia with ASCVD Risk (Phase 3 Dose) | 20 mg orally once daily | Once daily oral administration | Ongoing (continuous treatment for sustained LDL-C lowering) | This dose was used in the Phase 3 CORALreef Lipids and CORALreef HeFH trials. Selected based on dose-response modeling from Phase 2b data. Administered as add-on to existing lipid-lowering therapy including statins. |
| Hypercholesterolemia (Phase 2b Dose Range) | 6-30 mg orally once daily | Once daily oral administration | 8 weeks evaluated in Phase 2b | Phase 2b tested 6, 12, 18, and 30 mg doses. LDL-C reductions ranged from 41.2% to 60.9%. The 20 mg dose for Phase 3 was selected to optimize the efficacy-safety balance. |
Unlock full dosage protocols
Free access to complete dosing tables and protocol details.
150+ peptide profiles ยท 30+ comparisons ยท 18 research tools
๐Reconstitution Instructions
No reconstitution required. Enlicitide is formulated as an oral tablet for direct administration. This is a key advantage over injectable PCSK9 inhibitors that require subcutaneous injection.
๐งStorage Requirements
Storage conditions for enlicitide tablets have not been publicly disclosed in detail from clinical trial protocols. Standard oral tablet storage at room temperature, protected from moisture, is expected.
Community Dosing Protocols
Compare these clinical doses with what 15+ community members report using.
Based on 15+ community reports
View community protocolsResearch Tools
Before You Begin
Review safety warnings and contraindications before starting any protocol.
Investigational Status#
Enlicitide decanoate (MK-0616) is an investigational medication that has not yet received regulatory approval. Merck expects to submit for FDA approval in early 2026. All dosing information is derived from published clinical trial data. Dosing should only occur within the context of clinical trials or, once approved, under the guidance of a qualified cardiologist or lipid specialist.
Clinical Trial Dosing#
Phase 3 CORALreef Program (20 mg QD)#
Both Phase 3 CORALreef trials used the same dosing regimen:
- Dose: 20 mg orally once daily
- Formulation: Oral tablet
- Timing: On an empty stomach (based on Phase 2b protocol guidance)
- Duration: Continuous treatment (52-week data published)
- Background therapy: Added to existing lipid-lowering therapy including at least moderate-intensity statin
The 20 mg dose was selected based on dose-response modeling from the Phase 2b trial, balancing the near-maximal LDL-C lowering observed at 18-30 mg with the goal of minimizing unnecessary drug exposure.
Phase 2b Dose-Ranging (JACC 2023)#
The Phase 2b trial evaluated four dose levels over 8 weeks:
| Dose | LDL-C Reduction (vs Placebo) | Week 8 |
|---|---|---|
| 6 mg QD | 41.2% | P<0.001 |
| 12 mg QD | 55.7% | P<0.001 |
| 18 mg QD | 59.1% | P<0.001 |
| 30 mg QD | 60.9% | P<0.001 |
The relatively flat dose-response curve above 12 mg indicates that near-complete PCSK9 inhibition is achieved at moderate doses. The 20 mg dose was selected for Phase 3 as an optimal balance of efficacy, safety margin, and practical considerations.
Administration#
Oral Tablet Administration#
- Take one 20 mg tablet by mouth once daily
- Take on an empty stomach, approximately 30 minutes before the first meal
- Swallow whole
- Take at approximately the same time each day for consistency
Advantages Over Injectable PCSK9 Inhibitors#
Enlicitide's oral formulation eliminates several practical barriers associated with injectable PCSK9 antibodies:
| Feature | Enlicitide | Evolocumab/Alirocumab |
|---|---|---|
| Administration | Oral tablet | SC injection |
| Frequency | Once daily | Every 2-4 weeks |
| Cold chain required | No | Yes |
| Self-injection training | Not needed | Required |
| Injection site reactions | Not applicable | Common |
| Auto-injector device | Not needed | Required |
Monitoring Recommendations#
- Lipid panel: Baseline and at 4-12 weeks after initiation, then periodically
- Apolipoprotein B: Baseline and periodic (secondary efficacy marker)
- Lipoprotein(a): Baseline assessment (enlicitide also reduces Lp(a))
- Liver function: Baseline and periodic
- Creatine kinase: If myalgia develops (particularly with concomitant statin)
Combination Therapy#
In clinical trials, enlicitide was studied exclusively as add-on therapy to existing lipid-lowering regimens. Common background therapies included:
- Moderate or high-intensity statins
- Ezetimibe
- Other non-statin lipid-lowering agents
Enlicitide and statins work through complementary mechanisms: statins increase PCSK9 expression (which partially limits their efficacy), while enlicitide blocks this compensatory PCSK9 rise, producing additive LDL-C lowering.
Dosing Context#
Enlicitide belongs to the Vascular category of research peptides, with secondary relevance to the Metabolic category. Dosing protocols are derived from published Phase 2b (JACC 2023) and Phase 3 (NEJM and JAMA 2026) clinical trial data. These protocols are provided for research reference only and do not constitute medical advice.
Related Reading#
Subscribe to see vendor options
Free access to verified vendor scores, pricing, and suppliers.
150+ peptide profiles ยท 30+ comparisons ยท 18 research tools
Protocol updates
Get notified when we update dosing protocols or publish related comparisons.
Frequently Asked Questions About Enlicitide Decanoate
Explore Further
Medical Disclaimer
This website is for educational and informational purposes only. The information provided is not intended to diagnose, treat, cure, or prevent any disease. Always consult with a qualified healthcare professional before using any peptide or supplement.